{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T04:22:00Z","timestamp":1778559720138,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K16288"],"award-info":[{"award-number":["23K16288"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015064","name":"Tohoku Ika Yakka Daigaku","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015064","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.resinv.2025.07.011","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T03:33:10Z","timestamp":1753932790000},"page":"949-954","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of tocilizumab and corticosteroid treatment with baricitinib and corticosteroid treatment in severely and critically ill patients with coronavirus disease 2019"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6860-9734","authenticated-orcid":false,"given":"Hideya","family":"Itagaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8913-1864","authenticated-orcid":false,"given":"Jun","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruka","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2025.07.011_bib1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.07.011_bib2","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe Covid-19 pneumonia","volume":"384","author":"Rosas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.07.011_bib3","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.07.011_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.866441","article-title":"Initiation of tocilizumab or baricitinib were associated with comparable clinical outcomes among patients hospitalized with COVID-19 and treated with dexamethasone","volume":"13","author":"Wong","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.resinv.2025.07.011_bib5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/CCM.0000000000005756","article-title":"Outcomes and adverse effects of baricitinib versus tocilizumab in the management of severe COVID-19","volume":"51","author":"Peterson","year":"2023","journal-title":"Crit Care Med"},{"key":"10.1016\/j.resinv.2025.07.011_bib6","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19 (COV-Barrier): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2025.07.011_bib8","unstructured":"Ministry of Health. LaWoJ: visualizing the data: information on COVID-19 infections."},{"key":"10.1016\/j.resinv.2025.07.011_bib9","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/cid\/civ307","article-title":"Intravenous immunoglobulin and mortality in pneumonia patients with septic shock: an observational nationwide study","volume":"61","author":"Tagami","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2025.07.011_bib10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chron Dis"},{"key":"10.1016\/j.resinv.2025.07.011_bib11","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.resinv.2025.07.011_bib12","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.resinv.2025.07.011_bib13","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1177\/08971900231158931","article-title":"Tocilizumab versus baricitinib for the treatment of COVID-19 in patients with obesity","volume":"37","author":"Troyer","year":"2024","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.resinv.2025.07.011_bib14","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/phar.2438","article-title":"Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19","volume":"40","author":"Jorgensen","year":"2020","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.resinv.2025.07.011_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1293331","article-title":"Efficacy and safety of tocilizumab and baricitinib among patients hospitalized for COVID-19: a systematic review and meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.resinv.2025.07.011_bib16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(22)01109-6","article-title":"Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2025.07.011_bib17","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jinf.2022.04.040","article-title":"SARS-CoV-2 Omicron sublineage BA.2 replaces BA.1.1: genomic surveillance in Japan from september 2021 to March 2022","volume":"85","author":"Hirotsu","year":"2022","journal-title":"J Infect"},{"key":"10.1016\/j.resinv.2025.07.011_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2023-012328","article-title":"Severity and outcomes of Omicron variant of SARS-CoV-2 compared to Delta variant and severity of Omicron sublineages: a systematic review and metanalysis","volume":"8","author":"Relan","year":"2023","journal-title":"BMJ Glob Health"},{"issue":"12","key":"10.1016\/j.resinv.2025.07.011_bib19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3390\/diseases12050107","article-title":"Clinical outcomes among hospitalized COVID-19 patients who received baricitinib or tocilizumab in addition to standard of care","volume":"20","author":"Walker","year":"2024","journal-title":"Diseases"},{"issue":"19","key":"10.1016\/j.resinv.2025.07.011_bib20","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.07.011_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110439","article-title":"COVID-19 and severity of liver diseases: possible crosstalk and clinical implications","volume":"121","author":"Imam","year":"2023","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.resinv.2025.07.011_bib22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40268-020-00333-0","article-title":"Recommendations for dosing of repurposed COVID-19 medications in patients with renal and hepatic impairment","volume":"21","author":"Marra","year":"2021","journal-title":"Drugs R&D"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534525001121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534525001121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:27:04Z","timestamp":1772782024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534525001121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2212534525001121"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2025.07.011","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of tocilizumab and corticosteroid treatment with baricitinib and corticosteroid treatment in severely and critically ill patients with coronavirus disease 2019","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2025.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Japanese Respiratory Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}